Bexarotene is indicated for the treatment of skin manifestations of advanced stage cutaneous T-cell lymphoma (CTCL) in adult patients refractory to at least one systemic treatment.
For this indication, competent medicine agencies globally authorize below treatments:
Oral
300 - 300 mg per m² of body surface area (BSA)
From 300 To 300 mg per m² of body surface area (BSA) once every day
The recommended initial dose is 300 mg/m²/day. Initial dose calculations according to body surface area are as follows:
Recommended initial dose:
| Initial dose level (300 mg/m²/ημέρα) | Number of 75 mg bexarotene capsules | ||||
|---|---|---|---|---|---|
| Body Surface Area (m²) | Total daily dose (mg/ημέρα) | 0.88–1.12 | 300 | 4 | |
| 1.13-1.37 | 375 | 5 | |||
| 1.38-1.62 | 450 | 6 | |||
| 1.63-1.87 | 525 | 7 | |||
| 1.88-2.12 | 600 | 8 | |||
| 2.13-2.37 | 675 | 9 | |||
| 2.38-2.62 | 750 | 10 | |||
The 300 mg/m²/day dose level may be adjusted to 200 mg/m²/day then to 100 mg/m²/day, or temporarily suspended, if necessitated by toxicity. When toxicity is controlled, doses may be carefully readjusted upward. With appropriate clinical monitoring, individual patients may benefit from doses above 300 mg/m²/day. Doses greater than 650 mg/m²/day have not been evaluated in patients with CTCL. In clinical trials, bexarotene was administered for up to 118 weeks to patients with CTCL. Treatment should be continued as long as the patient is deriving benefit.